Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin …

Background Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for
whom treatment with peginterferon is not an option, or who have not had a response to prior …

Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV)
infection are associated with increased toxic effects in patients who also have cirrhosis. We …

Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with
advanced liver disease. We assessed the safety and efficacy of ledipasvir, sofosbuvir, and …

Background Chronic hepatitis C virus (HCV) infection is more prevalent among patients who
have chronic kidney disease than among those who do not have the disease. Patients with …

Much about the etiology, pathophysiology, natural course and optimal treatment of cystic
disease of the biliary tree remains under debate. Gastroenterologists, surgeons and …

Few studies have examined causes of death in long-term survivors of orthotopic liver
transplantation (OLT). We reviewed causes of death among 299 adult liver transplant recipients …

Historically, clinical trials of regimens to treat chronic infection with hepatitis C virus (HCV)
have used, as their primary efficacy endpoint, a sustained virological response (SVR)—…

Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat
population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that …

Context Among adult patients with liver disease, the ability to identify those most likely to have
cirrhosis noninvasively is challenging. Objective To identify simple clinical indicators that …